Mystery of Pediatric Hepatitis Cases Deepens as CDC Probe Continues
One more US death related to pediatric hepatitis was reported.
At-Home Test Helps With Birth Control Selection by Identifying Risk for Side Effects
Through hormone measurements and genetic analysis, the test can identify whether an individual is at increased risk for certain birth control side effects.
CDC Issues Guidance on COVID-19 Rebound After Paxlovid Treatment
Recent case reports suggest that some patients treated with Paxlovid may have a recurrence of COVID-19 symptoms 2 to 8 days after completing the 5-day course.
Odds of COVID-19 Mortality Lower for Women Receiving HRT
Receiving HRT within 6 months of recorded COVID-19 diagnosis linked to reduction in mortality risk.
PA Profile: FQHC Director Susanna Storeng, DMSc, PA-C
This month’s PA Profile features rural health care provider Susanna Storeng, DMSc, PA-C, DFAAPA, CPAAPA, who is director of a federally qualified community health center (FQHC).
Risk for Hospitalization for Heart Failure Down With SGLT-2i Treatment for T2D
Researchers conducted a population-based cohort study involving patients with T2D aged 18 years and older initiating treatment with SGLT-2i or metformin.
Pfizer-BioNTech COVID-19 Vaccine Elicits Strong Immune Response in Kids Under 5 After Third Dose
The trial included 1678 children who received a third dose of the 3µg formulation at least 2 months after the second dose of a 2-dose series at a time when Omicron was the predominant variant.
Children With High Schizophrenia Familial Risk Have Differential Neurocognitive Maturation
Data for this analysis were sourced from the Danish High Risk and Resilience Study. Participants were identified through the Danish Civil Registration System and Danish Psychiatric Central Research Register.
What Are the Effects of the COVID-19 Pandemic on People With Migraine?
Researchers sought to assess the qualitative effects of COVID-19 on patients with migraine who never tested positive for or been diagnosed with COVID-19.
Nonstimulant ADHD Treatment Option Approved for Adults
The approval was based on data from a phase 3 trial that assessed Qelbree in adults 18 to 65 years of age with ADHD.
- Loading...
Loading...
Next post in ADHD Information Center
Loading... 
Loading...